[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.55.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Birrell  MA, McCluskie  K, Wong  S, Donnelly  LE, Barnes  PJ, Belvisi  MG.  Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism.  FASEB J. 2005;19(7):840-841.PubMedGoogle Scholar
2.
Rahman  I, Biswas  SK, Kirkham  PA.  Regulation of inflammation and redox signaling by dietary polyphenols.  Biochem Pharmacol. 2006;72(11):1439-1452.PubMedGoogle ScholarCrossref
3.
Baur  JA, Pearson  KJ, Price  NL,  et al.  Resveratrol improves health and survival of mice on a high-calorie diet.  Nature. 2006;444(7117):337-342.PubMedGoogle ScholarCrossref
4.
Tomé-Carneiro  J, Gonzálvez  M, Larrosa  M,  et al.  Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective.  Ann N Y Acad Sci. 2013;1290:37-51.PubMedGoogle ScholarCrossref
5.
Wu  JM, Hsieh  TC.  Resveratrol: a cardioprotective substance.  Ann N Y Acad Sci. 2011;1215:16-21.PubMedGoogle ScholarCrossref
6.
Timmers  S, Auwerx  J, Schrauwen  P.  The journey of resveratrol from yeast to human.  Aging (Albany NY). 2012;4(3):146-158.PubMedGoogle Scholar
7.
Cantó  C, Auwerx  J.  Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?  Pharmacol Rev. 2012;64(1):166-187.PubMedGoogle ScholarCrossref
8.
Siemann  EH, Creasy  LL.  Concentration of the phytoalexin resveratrol in wine.  Am J Enol Vitic. 1992;43:49-52.Google Scholar
9.
Renaud  S, de Lorgeril  M.  Wine, alcohol, platelets, and the French paradox for coronary heart disease.  Lancet. 1992;339(8808):1523-1526.PubMedGoogle ScholarCrossref
10.
Liu  BL, Zhang  X, Zhang  W, Zhen  HN.  New enlightenment of French Paradox: resveratrol’s potential for cancer chemoprevention and anti-cancer therapy.  Cancer Biol Ther. 2007;6(12):1833-1836.PubMedGoogle ScholarCrossref
11.
Ghanim  H, Sia  CL, Abuaysheh  S,  et al.  An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol.  J Clin Endocrinol Metab. 2010;95(9):E1-E8.PubMedGoogle ScholarCrossref
12.
Ghanim  H, Sia  CL, Korzeniewski  K,  et al.  A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal.  J Clin Endocrinol Metab. 2011;96(5):1409-1414.PubMedGoogle ScholarCrossref
13.
Popat  R, Plesner  T, Davies  F,  et al.  A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.  Br J Haematol. 2013;160(5):714-717.PubMedGoogle ScholarCrossref
14.
Rotches-Ribalta  M, Andres-Lacueva  C, Estruch  R, Escribano  E, Urpi-Sarda  M.  Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets.  Pharmacol Res. 2012;66(5):375-382.PubMedGoogle ScholarCrossref
15.
Ferrucci  L, Bandinelli  S, Benvenuti  E,  et al.  Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study.  J Am Geriatr Soc. 2000;48(12):1618-1625.PubMedGoogle Scholar
16.
Pisani  P, Faggiano  F, Krogh  V, Palli  D, Vineis  P, Berrino  F.  Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres.  Int J Epidemiol. 1997;26(suppl 1):S152-S160.PubMedGoogle ScholarCrossref
17.
Guralnik  JM, Fried  LP, Simonsick  EM,  et al.  The Women’s Health and Aging Study: Health and Social Characteristics of Older Women with Disability. Bethesda, MD: National Institute on Aging; 1995:95-4009.
18.
Folstein  MF, Folstein  SE, McHugh  PR.  “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res. 1975;12(3):189-198.PubMedGoogle ScholarCrossref
19.
Levey  AS, Stevens  LA, Schmid  CH,  et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).  A new equation to estimate glomerular filtration rate.  Ann Intern Med. 2009;150(9):604-612.PubMedGoogle ScholarCrossref
20.
Ferrucci  L, Semba  RD, Guralnik  JM,  et al.  Proinflammatory state, hepcidin, and anemia in older persons.  Blood. 2010;115(18):3810-3816.PubMedGoogle ScholarCrossref
21.
Ferrucci  L, Corsi  A, Lauretani  F,  et al.  The origins of age-related proinflammatory state.  Blood. 2005;105(6):2294-2299.PubMedGoogle ScholarCrossref
22.
Friedewald  WT, Levy  RI, Fredrickson  DS.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;18(6):499-502.PubMedGoogle Scholar
23.
American Diabetes Association.  Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2006;29(suppl 1):S43-S48.PubMedGoogle Scholar
24.
Zamora-Ros  R, Urpí-Sarda  M, Lamuela-Raventós  RM,  et al; PREDIMED Study Investigators.  High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients.  Pharmacol Res. 2012;65(6):615-620.PubMedGoogle ScholarCrossref
25.
Zamora-Ros  R, Urpí-Sardà  M, Lamuela-Raventós  RM,  et al.  Resveratrol metabolites in urine as a biomarker of wine intake in free-living subjects: the PREDIMED Study.  Free Radic Biol Med. 2009;46(12):1562-1566.PubMedGoogle ScholarCrossref
26.
Blaut  M, Clavel  T.  Metabolic diversity of the intestinal microbiota: implications for health and disease.  J Nutr. 2007;137(3)(suppl 2):751S-755S.PubMedGoogle Scholar
27.
Nicholson  JK, Holmes  E, Kinross  J,  et al.  Host-gut microbiota metabolic interactions.  Science. 2012;336(6086):1262-1267.PubMedGoogle ScholarCrossref
28.
Yoshino  J, Conte  C, Fontana  L,  et al.  Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.  Cell Metab. 2012;16(5):658-664.PubMedGoogle ScholarCrossref
29.
Tomé-Carneiro  J, Gonzálvez  M, Larrosa  M,  et al.  One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.  Am J Cardiol. 2012;110(3):356-363.PubMedGoogle ScholarCrossref
30.
Timmers  S, Konings  E, Bilet  L,  et al.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.  Cell Metab. 2011;14(5):612-622.PubMedGoogle ScholarCrossref
31.
Elliott  PJ, Walpole  S, Morelli  L,  et al.  Resveratrol/SRT-501.  Drugs Future. 2009;34:291-295.Google ScholarCrossref
32.
Magyar  K, Halmosi  R, Palfi  A,  et al.  Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease.  Clin Hemorheol Microcirc. 2012;50(3):179-187.PubMedGoogle Scholar
33.
Tomé-Carneiro  J, Gonzálvez  M, Larrosa  M,  et al.  Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial.  Mol Nutr Food Res. 2012;56(5):810-821.PubMedGoogle ScholarCrossref
34.
Tomé-Carneiro  J, Larrosa  M, Yáñez-Gascón  MJ,  et al.  One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease.  Pharmacol Res. 2013;72:69-82.PubMedGoogle ScholarCrossref
35.
Poulsen  MM, Vestergaard  PF, Clasen  BF,  et al.  High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.  Diabetes. 2013;62(4):1186-1195.PubMedGoogle ScholarCrossref
36.
Walle  T, Hsieh  F, DeLegge  MH, Oatis  JE  Jr, Walle  UK.  High absorption but very low bioavailability of oral resveratrol in humans.  Drug Metab Dispos. 2004;32(12):1377-1382.PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    2 Comments for this article
    EXPAND ALL
    The truth is still far...
    Richard Semba | Richard D. Semba, Luigi Ferrucci, Benedetta Bartali, Mireia Urpí-Sarda, Raul Zamora-Ros, Kai Sun, Antonio Cherubini, Stefania Bandinelli, Cristina Andrés-Lacueva. Livelli di resveratrolo e d
    The study is completely removed from the foundations of scientific credibility and clear support of those who are still trying to gain by speculating on the health of the population. The circulating levels of resveratrol after wine intake, unless it is consumed a tanker of red wine, is small and completely devoid of flashy effects. It's obvious that an effective supplementation requires plasma quantitative significantly higher than the consumption of table wine, in order to assess the effectiveness of an active revolutionary as resveratrol. Your study should at least point out that the people of Tuscany is delighted by the quality of the wine hired ...
    CONFLICT OF INTEREST: Nessun potenziali conflitti o rilevanti interessi finanziari
    READ MORE
    Red wine and the French Paradox: another beautiful theory murdered by the ugly facts
    David L. Keller, MD, FACP | Independent
    The French paradox is the presence of low coronary heart disease (CHD) death rates in France, despite high levels of cholesterol and saturated fat in the French diet. This has been explained partially by a number of factors, including: French doctors under-reporting CHD on death certificates (this accounted for 20% of the paradox in one study); the fact that the French ingest ethanol in moderate doses continuously all day, every day, compared with other countries where most ethanol is consumed in binges on one or two days per week (ethanol binges produce less increase in HDL and inconsistent anti-platelet effects); the French eat large amounts of saturated fat from animal sources, compared with Americans who consume slightly less saturated fat overall, but much more of it is hydrogenated trans fat, which is thought to be more atherogenic; a time-lag effect whereby the CHD rates of today reflect fat consumption levels 30 or more years ago, when the French diet was less fatty compared with the U.S.; consumption of possibly protective fruits and vegetables is also higher in France than in the U.S.(1) French serum lipid levels do not explain the paradox: they have been shown to be very similar to levels in countries with lower fat consumption and higher CHD rates (2). The most widely touted theory has been that the French regularly consume red wine, which has antioxidants and anti-inflammatory components, such as polyphenols and resveratrol, which confer greater protection against atherosclerosis than the ethanol in wine can account for. This study provides observational evidence that red wine consumption (for which urinary resveratrol is an accurate marker) does not correlate with lower rates of CHD. A placebo-controlled double-blinded interventional study of pharmacological doses of resveratrol would be more conclusive, but might be hard to justify given these findings. The source of protection enjoyed by French hearts remains debatable.References1: Ferrières J, The French paradox: lessons for other countries. Heart. Jan 2004; 90(1): 107–111. PMCID: PMC17680132: Law M and Wald N. Why heart disease mortality is low in France: the time lag explanation BMJ. May 29, 1999; 318(7196): 1471–1480. PMCID: PMC1115846ReplyPermalinkShare Edit Delete
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Original Investigation
    July 2014

    Resveratrol Levels and All-Cause Mortality in Older Community-Dwelling Adults

    Author Affiliations
    • 1Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • 2Longitudinal Studies Section, National Institute on Aging, Baltimore, Maryland
    • 3New England Research Institute, Boston, Massachusetts
    • 4Nutrition and Food Science Department, Biomarkers and Nutrimetabolomics Laboratory, Food Technology Reference Net and Nutrition and Food Safety Research Institute (XaRTA and INSA ), Pharmacy School, University of Barcelona, Barcelona, Spain
    • 5Unit of Nutrition, Environment and Cancer, Cancer Epidemiology and Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain
    • 6Geriatrics and Geriatric Emergency Department, Istituto Nazionale di Riposo e Cura per Anziani V.E.II.–Istituto di Ricovero e Cura a Carattere Scientifico (INRCA-IRCCS), Ancona, Italy
    • 7Azienda Sanitaria, Florence, Italy
    JAMA Intern Med. 2014;174(7):1077-1084. doi:10.1001/jamainternmed.2014.1582
    Abstract

    Importance  Resveratrol, a polyphenol found in grapes, red wine, chocolate, and certain berries and roots, is considered to have antioxidant, anti-inflammatory, and anticancer effects in humans and is related to longevity in some lower organisms.

    Objective  To determine whether resveratrol levels achieved with diet are associated with inflammation, cancer, cardiovascular disease, and mortality in humans.

    Design  Prospective cohort study, the Invecchiare in Chianti (InCHIANTI) Study (“Aging in the Chianti Region”), 1998 to 2009 conducted in 2 villages in the Chianti area in a population-based sample of 783 community-dwelling men and women 65 years or older.

    Exposures  Twenty-four–hour urinary resveratrol metabolites.

    Main Outcomes and Measures  Primary outcome measure was all-cause mortality. Secondary outcomes were markers of inflammation (serum C-reactive protein [CRP], interleukin [IL]-6, IL-1β, and tumor necrosis factor [TNF]) and prevalent and incident cancer and cardiovascular disease.

    Results  Mean (95% CI) log total urinary resveratrol metabolite concentrations were 7.08 (6.69-7.48) nmol/g of creatinine. During 9 years of follow-up, 268 (34.3%) of the participants died. From the lowest to the highest quartile of baseline total urinary resveratrol metabolites, the proportion of participants who died from all causes was 34.4%, 31.6%, 33.5%, and 37.4%, respectively (P = .67). Participants in the lowest quartile had a hazards ratio for mortality of 0.80 (95% CI, 0.54-1.17) compared with those in the highest quartile of total urinary resveratrol in a multivariable Cox proportional hazards model that adjusted for potential confounders. Resveratrol levels were not significantly associated with serum CRP, IL-6, IL-1β, TNF, prevalent or incident cardiovascular disease, or cancer.

    Conclusions and Relevance  In older community-dwelling adults, total urinary resveratrol metabolite concentration was not associated with inflammatory markers, cardiovascular disease, or cancer or predictive of all-cause mortality. Resveratrol levels achieved with a Western diet did not have a substantial influence on health status and mortality risk of the population in this study.

    ×